Nymox Pharmaceutical Corporation NYMX
$ 0.2
-19.68%
Facebook
Twitter
ВКонтакте
Telegram
Сообщить о неточностиГодовой отчет за 2022 год
добавлен 09.11.2024
Nymox Pharmaceutical Corporation Мультипликаторы 2011-2024 | NYMX
Мультипликаторы по годам Nymox Pharmaceutical Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | -11.4 | -16.4 | -15.0 | -12.4 | -12.7 | -10.4 | -4.8 | -3.0 | -39.7 | -28.9 | -27.0 |
P/S |
- | - | 38535.6 | 1697.4 | 438.8 | 759.2 | 480.1 | 31.3 | 4.7 | 57.9 | 71.8 | 83.8 |
EPS |
- | -0.1 | -0.2 | -0.2 | -0.2 | -0.3 | -0.3 | -0.5 | - | - | - | - |
EV (Enterprise Value) |
- | 145 млн | 191 млн | 194 млн | 124 млн | 171 млн | 137 млн | 89.5 млн | 19.4 млн | 202 млн | 230 млн | 273 млн |
EBITDA per Share |
- | -0.15 | -0.16 | -0.19 | -0.18 | -0.25 | -0.279 | -0.472 | -0.134 | -0.143 | -0.229 | -0.294 |
EV/EBITDA |
-6.6 | -15.1 | -20.5 | -11.1 | -13.2 | -10.5 | -4.9 | -2.9 | -39.9 | -29.0 | -26.5 | |
PEG |
- | 1.04 | 0.92 | -0.42 | -0.37 | -0.4 | -0.25 | 0.02 | -0.42 | -1.01 | -1.24 | 0.74 |
P/B |
- | -283.5 | 89.8 | 57.1 | 18.7 | -135.9 | -212.3 | -27.4 | -3.0 | -30.1 | -28.1 | -46.6 |
P/CF |
- | -14.6 | -19.2 | -26.5 | -16.8 | -27.4 | -30.2 | -23.0 | -2.5 | -29.0 | -26.6 | -25.7 |
ROE % |
- | 2477.67 | -547.23 | -381.73 | -151.30 | 1073.46 | 2043.84 | 567.52 | 100.29 | 76.00 | 97.23 | 172.44 |
ROA % |
- | -868.81 | -270.27 | -239.79 | -131.18 | -1371.71 | -637.24 | -2512.37 | -322.94 | -507.93 | -434.82 | -151.40 |
ROCE % |
- | 2471.15 | -466.37 | -386.12 | -151.97 | 1057.95 | -1866.73 | 1148.01 | 154.30 | 155.09 | 395.85 | -326.71 |
Current Ratio |
0.8 | 0.7 | 2.0 | 2.7 | 7.5 | 0.4 | 1.5 | 0.3 | 0.3 | 0.2 | 0.5 | 1.8 |
DSO |
- | - | - | - | - | - | 12.5 | 36.8 | 83.6 | 63.1 | 73.3 | 46.1 |
DIO |
- | - | - | - | - | - | 5.5 | 85.7 | 185.5 | 29.8 | 61.1 | 29.7 |
DPO |
- | - | - | - | - | - | 2409.3 | 4189.7 | 3119.7 | 1038.3 | 1265.7 | 806.5 |
Операционный цикл |
- | - | - | - | - | - | 17.9 | 122.5 | 269.1 | 92.9 | 134.4 | 75.8 |
Финансовый цикл |
- | - | - | - | - | - | -2391.4 | -4067.1 | -2850.6 | -945.4 | -1131.3 | -730.7 |
Все данные представлены в валюте USD
Мультипликаторы поквартально Nymox Pharmaceutical Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | - | - | - | - | - | -0.03 | - | -0.06 | -0.04 | -0.04 | - | -0.04 | -0.08 | -0.04 | - | -0.05 | -0.04 | -0.05 | - | -0.09 | -0.05 | -0.06 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
- | - | - | - | - | -0.04 | -0.05 | -0.03 | - | -0.06 | -0.04 | -0.04 | - | -0.04 | -0.08 | -0.04 | - | -0.05 | -0.04 | -0.05 | - | -0.09 | -50.4 | -55.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
731.80 | 523.46 | -50.78 | -135.55 | 20031.89 | 20021.08 | 20218.61 | 20579.69 | 84.03 | 40.48 | 7.73 | -336.58 | -140.00 | -211.02 | -238.48 | -238.60 | 116.03 | 116.03 | 187.05 | 255.17 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-821.65 | -907.29 | -582.10 | -641.92 | -313.09 | -385.49 | -372.26 | -591.11 | -428.65 | -461.63 | -422.21 | -197.60 | -111.36 | -169.77 | -195.19 | -187.95 | -384.47 | -384.47 | -326.07 | -279.25 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
- | -208.09 | -416.17 | -500.73 | 19949.03 | 19938.25 | 20135.55 | 20495.39 | 81.92 | 37.57 | 3.99 | -340.01 | -141.95 | -213.45 | -240.60 | -240.03 | 114.95 | 114.95 | 186.45 | 254.60 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | - | 0.5 | 0.7 | 1.7 | 3.4 | 1.0 | 2.0 | 3.0 | 0.5 | 1.8 | 2.7 | 4.1 | 4.9 | 6.9 | 7.5 | 5.6 | 3.2 | 0.5 | 0.4 | - | - | - | 0.9 | - | - | - | 0.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Операционный цикл |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Финансовый цикл |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Все данные представлены в валюте USD